Bristol Myers Squibb (NYSE:BMY) Director Sells $240,578.00 in Stock

Posted by Francis Steltz on Nov 6th, 2026

Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) Director Julia Haller sold 3,800 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. The trade was a 11.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bristol Myers Squibb Stock Down 1.5%

Shares of NYSE BMY traded down $0.93 during midday trading on Friday, hitting $62.20. 9,094,785 shares of the company’s stock were exchanged, compared to its average volume of 12,013,368. The firm’s fifty day simple moving average is $62.44 and its 200-day simple moving average is $60.07. Bristol Myers Squibb Company has a twelve month low of $45.26 and a twelve month high of $68.64. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. The company has a market cap of $127.15 billion, a PE ratio of 13.79, a P/E/G ratio of 0.33 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. Bristol Myers Squibb had a net margin of 18.47% and a return on equity of 60.48%. The business had revenue of $13.07 billion for the quarter, compared to analyst estimates of $12.72 billion. During the same period last year, the firm posted $1.63 earnings per share. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. Research analysts predict that Bristol Myers Squibb Company will post 6.45 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.88%.

Institutional Trading of Bristol Myers Squibb

Several hedge funds have recently added to or reduced their stakes in BMY. Pinion Investment Advisors LLC raised its holdings in Bristol Myers Squibb by 3.8% during the third quarter. Pinion Investment Advisors LLC now owns 4,316 shares of the biopharmaceutical company’s stock worth $269,000 after acquiring an additional 158 shares in the last quarter. Altura Wealth Advisors Inc. grew its holdings in shares of Bristol Myers Squibb by 1.2% during the 3rd quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock worth $856,000 after purchasing an additional 161 shares in the last quarter. Capital City Trust Co. FL raised its position in Bristol Myers Squibb by 0.7% during the third quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock valued at $1,455,000 after purchasing an additional 167 shares in the last quarter. Eagle Bay Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 2.6% during the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock valued at $408,000 after purchasing an additional 168 shares during the last quarter. Finally, Blue Bell Private Wealth Management LLC increased its stake in shares of Bristol Myers Squibb by 21.1% in the third quarter. Blue Bell Private Wealth Management LLC now owns 969 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 169 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers Squibb reported 56-week Phase 3 results for Camzyos (mavacamten) in children with symptomatic obstructive hypertrophic cardiomyopathy. Sustained efficacy could support the drug’s potential in a broader patient population, though the report does not say that pediatric use has been approved. Article: Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial
Positive Sentiment: A multi-year AI alliance expands the company’s neuroscience efforts, potentially supporting future drug discovery, although the supplied report gives no financial terms or near-term revenue outlook. Article: Bristol Myers Squibb Expands Neuroscience Push With Multi Year AI Alliance
Positive Sentiment: Recent coverage also highlighted FDA accelerated approval for ZENBEXUS in multiple myeloma and positive trial updates in other diseases. These developments add to the pipeline narrative, though investors may weigh how much expected optimism is already reflected in the shares. Article: Bristol Myers Squibb Wins FDA Approval
Neutral Sentiment: A company director disclosed selling 3,800 shares. Insider sales can attract attention, but the filing alone does not establish the director’s reason or signal a change in the company’s outlook. SEC Form 4 filing
Negative Sentiment: A dividend-focused article flags potential pressure from an expected $1.5 billion–$2 billion decline in blood-thinner sales and the company’s debt burden. That raises questions about dividend sustainability, though the article does not establish that a cut is imminent. Article: Bristol Myers Squibb Yields Over 4%. Can Its Dividend Survive 2027?

Wall Street Analyst Weigh In

Several equities research analysts recently commented on BMY shares. Morgan Stanley dropped their target price on Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating on the stock in a report on Friday, October 30th. Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Bank of America reissued a “buy” rating on shares of Bristol Myers Squibb in a research note on Friday, October 30th. Piper Sandler cut their target price on shares of Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a research report on Monday, October 26th. Finally, Daiwa Securities Group boosted their price target on Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus target price of $65.46.

Check Out Our Latest Stock Report on BMY

Bristol Myers Squibb Company Profile

(Get Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease.

The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Bristol Myers Squibb was formed in 1989 through the merger of Bristol-Myers, founded in 1887, and the E.